readthroughSign in
Nov 5, 2026M&A

Pacira withdraws 2026 guidance, skips earnings release amid Viatris tender offer

In an 8-K dated November 5, 2026, Pacira said it will not report third-quarter results or hold a call while the Viatris acquisition is pending.

Pacira BioSciences, Inc. disclosed in a Form 8-K dated November 5, 2026 that it will forgo its usual quarterly financial disclosures because of a pending acquisition by Viatris Inc.

The filing recaps that on October 8, 2026, Pacira entered into an Agreement and Plan of Merger with Viatris Inc. and Peach Purchaser Sub Inc., a wholly owned subsidiary of Viatris, under which Purchaser commenced a tender offer on October 30, 2026 to buy all outstanding Pacira shares for $36.50 per share in cash.1 Following the tender offer, the merger agreement calls for Purchaser to merge with and into Pacira as soon as practicable after the offer closes, with Pacira surviving as a wholly owned subsidiary of Viatris under Delaware law.1

Because of the pending deal, Pacira said it will not issue an earnings release for the quarter ended September 30, 2026, nor hold a conference call to discuss financial results and recent developments.1 The company also said it is withdrawing its previously issued 2026 financial guidance and will not provide further updates to that guidance while the offer and merger are pending.1

The 8-K carries a November 5, 2026 date of report and was signed the same day by Kristen Williams, Pacira's Chief Administrative Officer and Secretary. The document does not separately state the date the filing was submitted to the SEC.

The filing also includes an extensive forward-looking statements section outlining risks to completing the transaction, including the possibility that required regulatory approvals are not obtained on the anticipated schedule or at all, and the possibility that competing offers may be made.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.